{"id":"W4281951137","doi":"10.1016/s0140-6736(22)00688-2","title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":297,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; University Hospital; Western University","funders":"Seres Therapeutics; Janssen Scientific Affairs; Crohn's and Colitis Foundation; Gilead Sciences; GlaxoSmithKline; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Ustekinumab; Adalimumab; Clinical endpoint; Crohn's disease; Internal medicine; Clinical trial; Population; Randomized controlled trial; Intention-to-treat analysis; Adverse effect; Randomization; Maintenance therapy; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001843575,0.001966175,0.004342376,0.0004522195,0.0005407682,0.001302678,0.001093487,0.002328811,0.007254016],"category_scores_gemma":[0.001760041,0.0007777069,0.002447416,0.0004720697,0.001533851,0.001496773,0.0005735611,0.004096531,0.001368068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007993931,"about_ca_system_score_gemma":0.0009347961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001056804,"about_ca_topic_score_gemma":0.002120447,"domain_scores_codex":[0.9993141,0.0003414853,0.00003993371,0.0001111196,0.00004681703,0.0001466202],"domain_scores_gemma":[0.9991043,0.0002683932,0.0001647778,0.0000880116,0.0000466361,0.0003278343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9887015,0.001520809,0.000209913,0.0002721628,0.0003967975,0.00001803772,0.00003335208,0.0001241773,0.0009494887,0.00004703096,0.0003979525,0.007328845],"study_design_scores_gemma":[0.9789339,0.01939418,0.0008800591,0.00001666613,0.0001775586,0.00001746629,0.00001335715,0.0001457606,0.0001255114,0.00007779378,0.000209593,0.000008039402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842905,0.008202916,0.0006524193,0.001268996,0.001091521,0.001681422,0.0008290654,0.0001788545,0.001804358],"genre_scores_gemma":[0.9843523,0.003534339,0.001523203,0.001702496,0.0006774098,0.002374691,0.001064162,0.00004373634,0.00472764],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007254016,"threshold_uncertainty_score":0.02426708,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04148110825086292,"score_gpt":0.2987136586084228,"score_spread":0.2572325503575599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}